System and Bundled Registration of Non-Sterile Medical Devices in Egypt

1. Key takeaways

Egypt provides two consolidated registration mechanisms for non-sterile devices, with different numbers of conditions and different logics of proof. System registration (Section 4.2.3) requires three conditions: the same legal manufacturer; a certificate (FSC, CE, USFDA CFG or DoC) stating that these devices constitute a system; and submission to a dedicated scientific committee confirming that the components complement one another as a system. Bundled registration (Section 4.2.4) requires six conditions: the same legal manufacturer; the same classification; the same proprietary name; a common intended use; a similar or close design; and inclusion within the range of permissible variants that the scientific committee can assess. Both mechanisms expressly state that sharing of raw materials, GMDN codes and patient populations is not required.

2. Legal basis

3. Expert insights

Insight one: system registration turns on documentary confirmation plus committee confirmation, while bundled registration turns on attribute identity.

Of the three conditions for system registration, the second is objective evidence (a certificate stating that the devices form a system) and the third is committee judgment (confirmation that the components complement one another). The six conditions for bundled registration are almost entirely objective attributes that the company can verify on its own (manufacturer, classification, proprietary name, intended use, design, variant range). Products that already hold a system-type certificate find system registration the easier route; those that do not must rely on attribute identity and take the bundled route. The strategic starting point is therefore a review of the existing certificate portfolio before any filing decision is made.

Insight two: the three elements both mechanisms waive are precisely the elements that most often block consolidation.

At the end of each of the two sections the guide repeats the same sentence: sharing of raw materials is not required, sharing of GMDN codes is not required, and sharing of patient populations is not required. This is not redundancy. It stands in deliberate contrast to the seven elements of the single registration number in Section 11.1, which do include raw materials and age group (patient population), while system and bundled registration open exceptions on exactly these two points. Companies blocked on divergent raw materials or GMDN codes should therefore pivot to the system or bundled pathway instead of forcing the single registration number framework onto an unsuitable portfolio.

Insight three: both system and bundled registration apply only to non-sterile devices.

The titles of both sections are expressly limited to non-sterile medical devices. Sterile devices fall outside the coverage of the two consolidation mechanisms and must be handled through the single registration number criteria or through separate registrations. This boundary matters commercially as well as technically: for portfolios that mix sterile and non-sterile versions of the same product family, the consolidation strategy must be built in two layers, with the sterile items planned on independent registration numbers from the outset rather than being retrofitted into a failed consolidation attempt.

Insight four: the sixth condition of bundled registration is an enabling clause whose real boundary sits with the committee.

The sixth condition reads that the devices must fall within the range of permissible variants that the scientific committee can assess. This means that even where the first five conditions are fully met, whether the grouping stands still depends on the committee’s acceptance of the variants. The design of the variant list (the gradients of model, specification and size) thus becomes part of the filing strategy rather than a purely commercial decision. Submitting an extreme spread of variants invites a committee refusal that fractures the whole grouping.

Insight five: the cost of a failed consolidation is re-filing as separate devices, not a simple correction.

Section 11.1 provides that devices differing in any of the listed elements will be registered as independent devices, each obtaining its own registration license and registration number. Section 5 in turn assigns the judgment of whether a difference is substantive to the committee. When a consolidation plan is overturned, the number of registration units changes directly, and with it the fees and the documentation volume. Companies should therefore stress-test their consolidation plan against the split scenario before submission, so that the fallback is priced and planned rather than improvised.

4. Practical recommendations

1. Check first whether a certificate already states that the devices form a system: if so, system registration is preferred, with fewer conditions and more direct proof.
2. Where no system certificate exists, self-assess against the six conditions: verify manufacturer, classification, proprietary name, intended use, design and variant range item by item.
3. Leave committee judgment room when designing the variant list: do not submit model gradients of extreme spread in a single filing.
4. Do not force the single registration number where raw materials or GMDN codes diverge: pivot to the system or bundled pathway instead.
5. Confirm the product is non-sterile: sterile devices are not covered by either consolidation mechanism.
6. Prepare the fallback before submitting a consolidation plan: run a stress calculation of registration numbers and fees under the split scenario.

5. Verification checklist

• □ The products are non-sterile devices
• □ The three conditions of system registration have been checked (same legal manufacturer / certificate states a system / committee confirms complementarity)
• □ The six conditions of bundled registration have been checked (manufacturer, classification, proprietary name, intended use, design, variant range)
• □ It has been confirmed that raw materials, GMDN codes and patient populations are not required conditions
• □ The variant list has been designed within the range the committee can be expected to accept
• □ The number of registration numbers and the fees under a split registration have been calculated for the failure case

Legal information verified as of 29 October 2026. The system and bundled registration rules described in this article follow the current text of Sections 4.2.3 and 4.2.4 of EDREX: GL.CAMD.002 Version 2.

• Egypt local resources: GRZAN assists manufacturers from the Chinese mainland and overseas with medical device registration, import approval and change applications before the Egyptian Drug Authority (EDA), including design of the registration applicant arrangement (importing company, local factory or scientific office), preparation for scientific committee assessment, argumentation of routes for obtaining free sale certificates from reference countries, Arabic localization of labels and instructions for use, and the establishment of vigilance systems and periodic reporting.
• Service capabilities: product attribute determination and risk classification (devices Class I–III / IVD Class A–D), registration and re-registration, applicability determination for system registration and bundled registration, three-category determination of changes, import approval and annual import plans, and support for vigilance reports and field safety corrective actions.
• Contact: hito.lin@grzan.cn; website www.grzan.cn.